Nautilus Biotechnology (NAUT) Interest Expenses (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Interest Expenses of $34.8 million for Q2 2026, down 4.59% sequentially from $36.5 million in Q1 2026, and down 2.84% YoY from $35.8 million in Q2 2025.
Nautilus Biotechnology (NAUT) Interest Expenses (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Interest Expenses for 7 years, with the latest figure at $34.8 million in Q2 2026.
- Quarterly Interest Expenses fell 2.84% year-over-year to $34.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $34.8 million (down 2.84% YoY) and the FY2025 annual result came in at $93.4 million, up 19.13% from the prior year.
- Interest Expenses declined to $34.8 million in Q2 2026 per NAUT's latest filing, from $36.5 million in the prior quarter.
- Over five years, Interest Expenses peaked at $49.8 million in Q2 2023 and troughed at -$5.1 million in Q4 2024.
- A 5-year average of $23.2 million and a median of $34.4 million in 2025 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2026: Interest Expenses sank 182.74% in 2024, then soared 1925.28% in 2026.
- Over 5 years, Interest Expenses stood at $1.1 million in 2022, then jumped by 462.09% to $6.2 million in 2023, then sank by 182.74% to -$5.1 million in 2024, then soared by 135.18% to $1.8 million in 2025, then soared by 1832.39% to $34.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $34.8 million, $36.5 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.78 Mn |
| Jun 30, 2026 | 34.78 Mn |
| Mar 31, 2026 | 36.46 Mn |
| Mar 31, 2026 | 36.46 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Sep 30, 2025 | 34.00 Mn |
| Jun 30, 2025 | 35.80 Mn |
| Jun 30, 2025 | 35.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | 41.15 Mn |
| Sep 30, 2024 | 41.15 Mn |
| Jun 30, 2024 | 42.90 Mn |
| Jun 30, 2024 | 42.90 Mn |
| Mar 31, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.70 Mn |